Anti-Cancer Effects
In Vitro Studies
NAM significantly reduced melanoma cell numbers in both human (A375, SK-MEL-28) and mouse (B16-F10) cell lines
It induced cell cycle arrest, with a 40% increase in G1-phase accumulation and about 50% decrease in S- and G2-phases.
NAM treatment led to a 10-fold increase in cell death and a 2.5-fold increase in apoptosis.
Metabolic Effects
NAM significantly increased NAD+, ATP, and Reactive Oxygen Species (ROS) levels in melanoma cells.
These metabolic changes likely contribute to NAM's anti-cancer activity.
SIRT2 Inhibition
NAM strongly inhibited SIRT2 activity in vitro, with an EC50 of 2 μM.
SIRT2 expression is significantly increased in metastatic melanoma patients compared to healthy controls.
Higher SIRT2 expression correlates with lower survival rates in melanoma patients.
In Vivo Studies
NAM significantly delayed tumor growth in a mouse melanoma model (p ≤ 0.0005).
It improved survival of melanoma-bearing mice (p ≤ 0.0001).
Anti-Inflammatory Benefits
NAM treatment led to a 3-fold increase in Interferon-gamma (IFN-γ) producing cells in treated mice.
The study found significant changes in the plasma levels of 6 cytokines (IL-5, Eotaxin, IL12(p40), IL-3, IL-10, and RANTES) in NAM-treated mice, suggesting modulation of the immune response.
Additional Insights
The study revealed that the expression of Niacin receptors HCAR2 and HCAR3 is almost abolished in human melanoma samples, which may have implications for NAM's mechanism of action.
This research provides strong evidence for NAM's potential as an anti-cancer agent, particularly against melanoma, while also highlighting its anti-inflammatory properties. These findings support the broader health benefits of Nicotinamide and suggest it could be a promising candidate for further clinical investigations in cancer treatment and prevention.
We use Nicotinamide in our product "Gray-Out"
Comments